Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E25.41 EPS (ttm)2.78 Insider Own0.10% Shs Outstand1.49B Perf Week4.27%
Market Cap104.72B Forward P/E7.43 EPS next Y9.49 Insider Trans10.61% Shs Float1.48B Perf Month11.04%
Income4.18B PEG6.20 EPS next Q2.29 Inst Own70.80% Short Float3.45% Perf Quarter-10.40%
Sales32.62B P/S3.21 EPS this Y4.80% Inst Trans-0.01% Short Ratio4.50 Perf Half Y-13.31%
Book/sh-5.79 P/B- EPS next Y7.00% ROA6.80% Target Price86.58 Perf Year-24.38%
Cash/sh3.65 P/C19.34 EPS next 5Y4.10% ROE-58.90% 52W Range62.66 - 96.60 Perf YTD-23.52%
Dividend4.28 P/FCF15.68 EPS past 5Y7.60% ROI21.80% 52W High-27.01% Beta0.96
Dividend %6.07% Quick Ratio0.80 Sales past 5Y11.80% Gross Margin77.40% 52W Low12.53% ATR1.52
Employees30000 Current Ratio0.90 Sales Q/Q-0.30% Oper. Margin21.80% RSI (14)65.80 Volatility2.35% 2.19%
OptionableYes Debt/Eq- EPS Q/Q-60.60% Profit Margin12.50% Rel Volume0.71 Prev Close70.83
ShortableYes LT Debt/Eq- EarningsOct 25 BMO Payout148.90% Avg Volume11.33M Price70.51
Recom2.50 SMA205.78% SMA504.63% SMA200-9.45% Volume8,091,982 Change-0.45%
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Sep-13-19 03:29PM  Dividend Growth ETFs for Long Term Investors Zacks
11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
Sep-12-19 06:22PM  Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan Reuters
05:46PM  Gilead Tops List of Most Innovative Drug Companies
04:09PM  Humira Sales Will Crash To $3 Billion Why AbbVie Stock Got An Upgrade Investor's Business Daily
11:47AM  Buy AbbVie Stock, Because Its Deal for Allergan Just Might Work, Analyst Says
10:54AM  AbbVie Stock Rises After UBS Upgrades To Buy
Sep-11-19 09:32AM  4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks
09:15AM  Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio Zacks
Sep-10-19 10:55AM  10 Healthcare Stocks to Buy Despite the Headlines InvestorPlace
Sep-09-19 05:45PM  AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Zacks
11:20AM  The Zacks Analyst Blog Highlights: Microsoft, Home Depot, AbbVie, Disney and Host Hotels Zacks
Sep-08-19 05:04PM  Weekly Top Insider Buys Highlight for the Week of Sept. 6
07:00AM  3 Stocks to Buy With Dividends Yielding More Than 6% Motley Fool
Sep-06-19 01:56PM  Top Stock Reports for Microsoft, Home Depot & AbbVie Zacks
10:43AM  AbbVie Declares Quarterly Dividend PR Newswire
09:23AM  Can Copycats Take On $198 Billion In Blockbuster Biotech Sales? Investor's Business Daily
Sep-05-19 04:51PM  3 Special Situations Gurus Are Buying
10:18AM  J&J's Stelara Gets Approval in EU for Ulcerative Colitis Zacks
Sep-04-19 10:00AM  AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily
07:00AM  3 Lessons From AbbVie's $5.8 Billion Blunder With Cancer Drug Rova-T Motley Fool
Sep-03-19 03:35PM  Why Bank of America Says Dividend Stocks are the Only Play Now Investopedia
09:21AM  The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie Zacks
Sep-01-19 07:30AM  3 High-Yield Dividend Stocks to Buy on Sale Motley Fool
Aug-31-19 06:15PM  Top Marijuana Stocks That Pay Dividends Investopedia
Aug-30-19 10:21AM  AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails Zacks
10:11AM  Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs Zacks
Aug-29-19 05:18PM  Big Pharma kills signature drug at center of $5.8 billion South S.F. deal American City Business Journals
09:35AM  UPDATE 1-AbbVie abandons late-stage lung cancer asset Rova-T Reuters
09:29AM  AbbVie Discontinues Phase III Trial of Drug to Treat Small-Cell Lung Cancer
09:16AM  AbbVie is shutting down its troubled Rova-T R&D program MarketWatch
08:59AM  AbbVie terminates late-stage lung cancer trial Reuters
08:45AM  AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program PR Newswire
Aug-28-19 03:45PM  UPDATE 1-FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients Reuters
10:15AM  Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion Zacks
Aug-27-19 02:03PM  Should You Buy AbbVie for the Dividend? Motley Fool
11:36AM  Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis Zacks
10:55AM  Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy? Zacks
08:00AM  AbbVie to Present at the Morgan Stanley Healthcare Conference PR Newswire
06:41AM  This dividend-stock strategy is for investors who want an attractive monthly income stream MarketWatch
06:00AM  Why Jim Cramer's Negative Take on Pfizer Is Flat-Out Wrong Motley Fool
Aug-26-19 11:38AM  The Search for High Yield: Argus Thematic Portfolios Athena Preview
10:30AM  Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study Zacks
09:15AM  Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks
Aug-25-19 09:30AM  AbbVie (ABBV) Down 1% Since Last Earnings Report: Can It Rebound? Zacks
07:00AM  Better Buy: AbbVie vs. Johnson & Johnson Motley Fool
Aug-24-19 05:36PM  Weekly Top Insider Buys Highlight for the Week of Aug. 23
Aug-23-19 08:19PM  Factbox: Pending mergers and acquisitions involving U.S. firms that need Chinese approval Reuters
10:36AM  Amgen Presents Positive Data From Rituxan Biosimilar Study Zacks
09:40AM  Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit Zacks
Aug-22-19 01:17PM  Here's What You Should Know About AbbVie Inc.'s (NYSE:ABBV) 6.3% Dividend Yield Simply Wall St.
Aug-21-19 06:03PM  Synlogic Discontinues Development of SYNB1020, Stock Down Zacks
07:15AM  AbbVie Stock Slipped to a New Low, and One Exec Scooped Up Shares
04:56AM  Pot Entrepreneurs Can Now Get an MBA in Cannabis Investopedia
Aug-20-19 06:38PM  Bayer Sells Animal Health Division to Elanco: Now What? Zacks
11:50AM  The Time is Right For This Dividend ETF ETF Trends
11:06AM  Buy AbbVie Stock Because You Cant Ignore How Cheap It Is
09:44AM  Here's Why Allergan is Outperforming Its Industry Of Late Zacks
06:00AM  AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira Motley Fool
05:48AM  High-Dividend Stocks on Historic Discount as Yields Plunge, says Goldman Investopedia
Aug-19-19 11:49AM  Stocks To Buy: Is It Time To Buy Or Sell These Large-Cap Stocks? Investor's Business Daily
08:58AM  AbbVie Rises 3%
08:04AM  AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA Zacks
06:00AM  5 Biggest New Drug Approvals Potentially on the Way in 2019 Motley Fool
Aug-16-19 04:25PM  How AbbVie Plans To Take On Pfizer, Lilly And Kick Its Humira Habit Investor's Business Daily
04:20PM  How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals Investor's Business Daily
02:06PM  FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA MarketWatch
12:49PM  UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr Reuters
12:43PM  AbbVie Receives FDA Approval of RINVOQ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis PR Newswire
09:19AM  Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe Zacks
Aug-15-19 03:36PM  The Top Pharma Stocks for 2019 Investopedia
01:49PM  13 High-Yield Dividend Stocks to Watch Kiplinger
Aug-14-19 09:00PM  5 Top Cancer-Fighting Stocks to Buy Now Motley Fool
05:17PM  How Tesla has Become Most Profitable Short Bet at $2.75 Billion Investopedia
09:24AM  Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study Zacks
07:59AM  Correction: Allergan sale Financial Times
05:00AM  Defensive Stocks on Sale Morningstar
12:00AM  Elliott bags Goldmans Barg Financial Times
Aug-13-19 09:35AM  Should Value Investors Consider AbbVie (ABBV) Stock Now? Zacks
06:00AM  5 Biggest New Drugs Approved in 2019 So Far Motley Fool
01:04AM  JPMorgan Chase set to scoop record fee for Allergan sale Financial Times
Aug-12-19 12:12PM  10 Medical Marijuana Stocks to Cure Your Portfolio InvestorPlace
07:40AM  3M Stock Isnt Crumbling, but Its No Bargain Either InvestorPlace
05:00AM  5 Big Pharma Showdowns to Watch
Aug-11-19 09:00AM  3 Embarrassingly Cheap Dividend Stocks Motley Fool
08:14AM  3 Top Stocks With High Dividend Yields Motley Fool
07:00AM  AbbVie Insiders Bought Up the Stock as It Traded to New Lows
Aug-09-19 09:50AM  Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients Zacks
09:15AM  Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks
Aug-08-19 04:30AM  AbbVie: The Right Mixture for the Perfect Stock
12:37AM  CytomX Therapeutics, Inc. (CTMX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 12:37PM  Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 03:00PM  Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie Motley Fool
01:19PM  Allergan beats second-quarter expectations, boosts full-year guidance MarketWatch
12:01PM  Despite Historic Market Performance, IMX Remains Relatively Unchanged Benzinga
11:56AM  Top Research Reports: Chevron, AbbVie, Phillips 66 & More Zacks
10:19AM  Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up Zacks
09:58AM  Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand Reuters
09:51AM  Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand Reuters
05:37AM  Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donoghoe NicholasSVP, Enterprise InnovationAug 29Buy66.197,525498,05713,090Aug 30 04:08 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsAug 16Buy64.4415,5521,002,16965,304Aug 20 04:16 PM
AUSTIN ROXANNE SDirectorAug 01Buy65.6625,0001,641,400117,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 31Buy66.0230,0001,980,69092,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 30Buy66.3510,000663,50062,114Jul 31 04:46 PM
Gosebruch Henry OEVP, Chief Strategy OfficerJul 29Buy67.2830,0002,018,38575,763Jul 31 04:46 PM
AUSTIN ROXANNE SDirectorJun 26Buy67.5011,500776,25052,114Jun 28 04:47 PM
CHASE WILLIAM JEVP, Finance & AdministrationJun 26Buy67.3030,4002,045,920169,552Jun 28 04:47 PM
RAPP EDWARD JDirectorJun 26Buy67.307,500504,75030,662Jun 28 04:48 PM
Durkin Brian LVP, ControllerMar 25Sale79.6947537,8539,121Mar 25 04:34 PM
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM